Global Fund to support diagnosis and treatment of AIDS-related fungal infections

Posted .

denning1GAFFI visits The Global Fund to discuss funding models for opportunistic infections in AIDS. With the shift in funding model used by the Global Fund for AIDS, TB and Malaria to include a more complete package of care for HIV-infected patients, the major life-threatening fungal infections come high up on the priority list. However estimating the cost of identifying these infections and then treating them differs in each country, in adults and children and by infection.

GAFFI’s country by country estimates of fungal disease burden provide an initial source for estimating the numbers of cases. GAFFI has also ascertained the cost of antifungal drugs in most countries. Individual countries can provide the actual medical non-drug costs according to local wages and monitoring costs.

GAFFI’s President Professor David Denning said; “The welcome shift in the Global Health’s funding model will allow many more lives of HIV-infected patients to be saved; Those presenting very ill with advanced AIDS; those in the first year of ART before immune recovery and in the 11% on ART whose HIV virus is resistant.”

With 75 countries applying for The Global Fund’s funding this year, estimating the costs of care over and above antiretroviral therapy and monitoring is a substantial task. GAFFI will work with UNAIDS and The Global Fund to develop equitable and realistic cost estimates, for each country, which can then be negotiated, and subsequently refined in the light of experience.